Paradigm Biopharmaceuticals Limited (ASX:PAR) is an ASX-listed biotechnology company focused on repurposing Pentosan Polysulfate Sodium (PPS), an FDA approved drug that has a long track record of safely treating inflammation over 60 years. The Company’s primary focus is on repurposing PPS (under the name ZILOSUL®) to treat Osteoarthritis (OA) – a market with over 31m sufferers in the USA alone.
More details about our programme can be found here.
Current shareholders click here to access and update your personal details.
Paradigm presents at Small Cap Virtual Conference on Friday 27 March, 2020
Paradigm Biopharmaceuticals Ltd is pleased to provide an opportunity for shareholders and investors to view a virtual presentation by CEO, Paul Rennie, who presented at the NWR Small Cap Virtual Conference on Friday 27 March.
Click here to view a video of the virtual presentation.